This invention concerns HIV replication inhibitors of formula

[Image Omitted]

the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a¹=a²-a³=a⁴- and -b¹=b²-b³=b⁴- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R¹is hydrogen; aryl; formyl; C_1-6alkylcarbonyl; C_1-6alkyl; C_1-6alkyloxycarbonyl; substituted C_1-6alkyl, C_1-6alkylcarbonyl, C_1-6alkyloxycarbonyl, C_1-6alkylcarbonyloxy; substituted C_1-6alkyloxyC_1-6alkylcarbonyl; R²is hydroxy, halo, optionally substituted C_1-6alkyl, C_3-7cycloalkyl, optionally substituted C_2-6alkenyl, optionally substituted C_2-6alkynyl, C_1-6alkyloxy, C_1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C_1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, â€”S(â• O)_pR⁶, â€”NHâ€”S(â• O)_pR⁶, â€”C(â• O)R⁶, â€”NHC(â• O)H, â€”C(â• O)NHNH₂, â€”NHC(â• O)R⁶, â€”C(â• NH)R⁶or a 5-membered heterocycle; X₁is â€”NR⁵â€”, â€”NHâ€”NHâ€”, â€”Nâ• Nâ€”, â€”Oâ€”, â€”C(â• O)â€”, C_1-4alkanediyl, â€”CHOHâ€”, â€”Sâ€”, â€”S(â• O)_pâ€”, â€”X₂â€”C_1-4alkanediyl- or â€”C_1-4alkanediyl-X₂â€”; R³is NHR¹³; NR¹³R¹⁴; â€”C(â• O)â€”NHR¹³; â€”C(â• O)â€”NR¹³R¹⁴; â€”C(â• O)â€”R¹⁵; â€”CHâ• Nâ€”NHâ€”C(â• O)â€”R¹⁶; substituted C_1-6alkyl; optionally substituted C_1-6alkyloxyC_1-6alkyl; substituted C_2-6alkenyl; substituted C_2-6alkynyl; C_1-6alkyl substituted with hydroxy and a second substituent; â€”C(â• Nâ€”Oâ€”R⁸)â€”C_1-4alkyl; R⁷; or â€”X₃â€”R⁷; R⁴is halo, hydroxy, C_1-6alkyl, C_3-7cycloalkyl, C_1-6alkyloxy, cyano, nitro, polyhaloC_1-6alkyl, polyhaloC_1-6alkyloxy, aminocarbonyl, C_1-6alkyloxycarbonyl, C_1-6alkylcarbonyl, formyl, amino, mono- or di(C_1-4alkyl)amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.